Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease
AUTHORS
Snyder, et al
Programs
OPN-2853 , OPN-51107
https://doi.org/10.3389/fonc.2021.760789
Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma
AUTHORS
Gordon, et al
Programs
OPN-2853
Download PDF
Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
AUTHORS
Mims, et al
Programs
OPN-2853
Download PDF
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
AUTHORS
Cummin, et al
Programs
OPN-2853 , OPN-51107
https://doi.org/10.1182/bloodadvances.2020002231
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
AUTHORS
Pemmaraju, et al
Programs
OPN-2853
Download PDF
Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors
AUTHORS
Patnaik, et al
Programs
OPN-2853
Download PDF